Filing Flows › Profound Medical (PROF) › Q3 2026 › vs Q2 2026
Profound Medical (PROF) Q3 2026 vs Q2 2026 (quarter over quarter)
Profound Medical's revenue rose $7.3M (+296%) from $2.5M in Q2 2026 to $9.8M in Q3 2026. The biggest changes: Capital equipment +$4.9M (+557%); Recurring - non-capital +$2.5M (+155%).
Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%, net loss $7.7M, operating cash flow −$5.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Capital equipment | $5.7M | $871K | $4.9M | +557% |
| Recurring - non-capital | $4.1M | $1.6M | $2.5M | +155% |
| Revenue | $9.8M | $2.5M | $7.3M | +296% |
| Other income, net | $95K | $1.6M | −$1.5M | -94% |
| Income tax benefit | $4K | −$55K | $59K | — |
| Net loss | $7.7M | $9.5M | −$1.8M | -19% |
| Costs & expenses | $17.7M | $13.6M | $4.0M | +30% |
| Operating costs | $17.7M | $13.5M | $4.1M | +30% |
| Cost of revenue | $2.1M | $536K | $1.6M | +301% |
| Research & development | $5.8M | $5.7M | $152K | +3% |
| SG&A | $9.7M | $7.4M | $2.3M | +32% |
| Operating cash sources | $7.7M | $9.5M | −$1.8M | -19% |
| Depreciation & amortization | $133K | $135K | −$2K | -1% |
| Share-based compensation | $257K | $874K | −$617K | -71% |
| Working capital & other | $2.3M | −$2.8M | $5.1M | — |
| Cash used in operations | $5.0M | $11.3M | −$6.3M | -56% |
| Net loss absorbed | $7.7M | $9.5M | −$1.8M | -19% |
Questions
How much did Profound Medical's revenue grow quarter over quarter in Q3 2026?
Profound Medical's revenue rose $7.3M (+296%) from $2.5M in Q2 2026 to $9.8M in Q3 2026.
What drove Profound Medical's revenue change in Q3 2026?
Capital equipment +$4.9M (+557%); Recurring - non-capital +$2.5M (+155%).